UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 14

of 'Cancer of the ovary, fallopian tube, and peritoneum: Surgery for recurrent cancer'

14
TI
The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer.
AU
Oksefjell H, Sandstad B, TropéC
SO
Ann Oncol. 2009 Feb;20(2):286-93. Epub 2008 Aug 25.
 
BACKGROUND: The aim of this study was to investigate the benefit of secondary cytoreduction (SCR) in the first relapse in epithelial ovarian cancer and to attempt to define selection criteria for SCR.
PATIENTS AND METHODS: A retrospective population-based study on recorded information from 789 patients treated at the Norwegian Radium Hospital during 1985-2000 for their initial recurrence. In all, 217 had SCR and 572 were treated with chemotherapy alone.
RESULTS: Median survival time (MST) was 1.1 years for the chemotherapy group. Complete optimal cytoreduction (COC) was achieved in 35% of all 217 patients, in 49% of the patients operated with debulking intent and in 52% if bowel surgery was done with debulking intent. MST was 4.5 versus 0.7 years for 0 versus>2 cm residual disease, respectively. Residual disease after SCR, treatment-free interval (TFI) and age were found to be prognostic factors for overall survival (OS) in multivariate analysis. Localised tumour was found to be the only significant factor to predict COC.
CONCLUSIONS: SCR followed by chemotherapy gives a clear survival benefit compared with chemotherapy and should be offered when the tumour is localised. The combination of COC, TFI>24 months and age</=39 years identifies a group of patients with the best OS.
AD
Department of Gynaecological Oncology, The Norwegian Radium Hospital, Oslo, Norway. halldis.oksefjell@radiumhospitalet.no
PMID